Skip to main content
Equibles
MTRI logo

MTRI · InMed Pharmaceuticals Inc. · Webcasts, Transcripts & Audio

Track MTRI — free

Use MTRI with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research MTRI.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$18.79 +0.44 (+2.37%) Q4 2021 earnings call transcript
Rebalance outlook locked
Going-concern doubt — flagged Nov 3, 2026

Substantial doubt about the company's ability to continue as a going concern.

“We have concluded that there is substantial doubt about our ability to continue as a going concern within one year after the date that the condensed consolidated financial statements are issued.”
View the 10-Q filed Nov 3, 2026
Market Cap
$8.58M
Shares
549,374
Volume · Nov 13 7698 Avg daily vol (6 sessions) 62.9K

InMed Pharmaceuticals Inc. Webcasts

Earnings calls, investor updates, investor days and conferences for InMed Pharmaceuticals Inc. (MTRI), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Pull transcripts and briefs through the earnings call transcript API or MCP → Add these events to your calendar (.ics)

Embed InMed Pharmaceuticals Inc. earnings calls on your site

Pick a widget, match your page, then paste the code where it should appear.

Widget
Theme
Accent color Pro

Match your site's colors with Pro. The Equibles credit stays on every plan.

Embed code 

                    
The widget credits Equibles and keeps the link below it on every plan.

                

            


            

                Preview
                
            

        

        
    

    




    
    
    


        

    

        

            

                Key facts
                    
                        CIK
                        1728328
                    
                    
                        13F (30d)
                        3 filings
                        3 filers
                    
                    
                    
                         Visit website
                        
                    
                    
                         Investor relations